Clinical Feasibility Study, Implantable Tibial Nerve Stimulator (ITNS)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04115228

Enrollment

Registered

2019-10-03

Start date

2019-10-09

Completion date

2021-03-03

Last updated

2022-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder

Brief summary

Study objectives: To report feasibility data for safety and effectiveness of the study device. Study device: Nine Continents Medical implantable tibial nerve stimulator (ITNS) model 9C-680 with programmer model 9C-580. Intended use: The study device is intended for treatment of the symptoms of overactive bladder (OAB), including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments. Type of design: Single-arm longitudinal design. Study sites: Single site, in the United States. Study duration: One year total, comprising six months for enrolling and implanting 10 subjects, and 26 weeks for follow-up.

Interventions

DEVICEImplantation and neuromodulation therapy

The study device is an autonomous permanent implant for neuromodulation targeting the posterior tibial nerve. It does not require an external power source or charger.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DEVICE_FEASIBILITY

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

At pre-screening: * Age 18 years or older; * Documented diagnosis of overactive bladder; * Documented failed behavioral intervention and/or physical therapy; * Documented failed first drug for overactive bladder; and * Documented failed second drug for overactive bladder. At screening: * Life expectancy of at least one year; * Capable of tolerating the implantation procedure; * Ambulatory and able to use the toilet independently and without difficulty; and * Able to sense and tolerate posterior tibial nerve stimulation (transcutaneous test). Based on pre-therapy voiding diary: * Average daily voids during waking hours ≥ 11; * Average daily voids interrupting sleep ≥ 2.0; * Average daily voids associated with urgency ≥ 4; or * Average daily incontinence episodes ≥ 1.

Exclusion criteria

At pre-screening: * Predominant stress incontinence; * For females, pelvic organ prolapse quantification (POP-Q) ≥ grade II; * Neurologic disease, e.g. MS, Parkinson's; * Abnormal upper urinary tract function; * Neurogenic bladder; * Bladder stone or tumor; * Body mass index (BMI) \> 40; * Chronic pelvic pain; * Urinary fistula; * Peripheral neuropathy; * History of failed neuromodulation for overactive bladder; * Uncontrolled bleeding disorder; * End stage renal failure, glomerular filtration rate (GFR) \< 35, or dialysis; * Untreated diabetes or A1C \> 7; * Implanted pacemaker, defibrillator, or neurostimulator; * History of pelvic cancer within the past two years; * Condition requiring magnetic resonance imaging (MRI); * Condition requiring diathermy; * Metallic implant in planned site of study device; * For females, pregnant; * For females, planning to become pregnant; * For females, given birth in the last 6 months; or * For females, of child-bearing potential and not willing to practice a medically-approved method of birth control during the study. At screening: * Anatomical restriction preventing device placement; * Skin lesions or compromised skin at the implant site; * For females, pelvic organ prolapse quantification (POP-Q) ≥ grade II; * Post-void residual \> 150 cc; * Urinary tract mechanical obstruction due to urethral stricture; * Urinary tract mechanical obstruction due to bladder neck contracture; * In males, urinary tract mechanical obstruction due to benign prostatic hyperplasia (BPH); * Vesicoureteral reflux; * Cystoscopic abnormalities that could be malignant; * Current cystitis; * Current urethritis; * Gross hematuria; * In females, positive pregnancy test; * Any other medical condition with potential effect on bladder function, as assessed by investigator; or * Any other medical condition that could compromise the safety of the subject, as assessed by investigator.

Design outcomes

Primary

Measure	Time frame	Description
Percent Change of Urinary Incontinence Frequency From Baseline to 13 Weeks	Baseline to 13 weeks	For a participant analyzed, let x0 = average number of voids with leakage per 24 hours in first 72 hours of baseline diary, x1 = average number of voids with leakage per 24 hours in first 72 hours of 13-week diary, and x = percent change of urinary incontinence frequency from baseline to 13 weeks. Then x = 100 \* (x1 - x0) / x0. For example, a participant with an average of 4 voids with leakage per 24 hours in the first 72 hours of the baseline diary and 2 voids with leakage per 24 hours in the first 72 hours of the 13-week diary would have a percent change of urinary incontinence frequency from baseline to 13 weeks of 100 \* (2 - 4) / 4 = -50.
Percent Change of Excess Voiding Frequency During Waking Hours From Baseline to 13 Weeks	Baseline to 13 weeks	For a participant analyzed, let x0 = average number of voids during waking hours per 24 hours in first 72 hours of baseline diary, x1 = average number of voids during waking hours per 24 hours in first 72 hours of 13-week diary, and x = percent change of excess voiding frequency during waking hours from baseline to 13 weeks, where excess means voids during waking hours exceeding 7 per 24 hours. Then x = 100 \* (x1 - x0) / (x0 - 7). For example, a participant with an average of 16 voids during waking hours per 24 hours in the first 72 hours of the baseline diary and an average of 10 voids during waking hours per 24 hours during the first 72 hours of the 13-week diary would have a percent change of excess voiding frequency during waking hours from baseline to 13 weeks of 100 \* (10 - 16) / (16 - 7) = -67.
Percent Change of Frequency of Voids Awakening From Sleep From Baseline to 13 Weeks	Baseline to 13 weeks	For a participant analyzed, let x0 = average number of voids awakening from sleep per 24 hours in first 72 hours of baseline diary, x1 = average number of voids awakening from sleep per 24 hours in first 72 hours of 13-week diary, and x = percent change of frequency of voids awakening from sleep from baseline to 13 weeks. Then x = 100 \* (x1 - x0) / x0. For example, a participant with an average of 2 voids awakening from sleep per 24 hours in the first 72 hours of the baseline diary and an average of 1 void awakening from sleep per 24 hours during the first 72 hours of the 13-week diary would have a percent change of frequency of voids awakening from sleep from baseline to 13 weeks of 100 \* (1 - 2) / 2 = -50.
Percent Change of Frequency of Voids With Urgency From Baseline to 13 Weeks	Baseline to 13 weeks	For a participant analyzed, let x0 = average number of voids with urgency per 24 hours in first 72 hours of baseline diary, x1 = average number of voids with urgency per 24 hours in first 72 hours of 13-week diary, and x = percent change of frequency of voids with urgency from baseline to 13 weeks, where voids with urgency means voids self-reported with some or severe urgency, or leakage. Then x = 100 \* (x1 - x0) / x0. For example, a participant with an average of 8 voids with urgency per 24 hours in the first 72 hours of the baseline diary and an average of 5 voids with urgency per 24 hours during the first 72 hours of the 13-week diary would have a percent change of frequency of voids with urgency from baseline to 13 weeks of 100 \* (5 - 8) / 8 = -37.5

Secondary

Measure	Time frame	Description
Change of Score on an Overactive Bladder Questionnaire Short-form (OAB-q SF) Symptom Bother Subscale From Baseline to 13 Weeks	Baseline to 13 weeks	The overactive bladder questionnaire short-form (OAB-q SF) symptom bother subscale ranges from 0 to 100, and higher symptom bother scores indicate greater symptom bother ( worse outcome). For a participant analyzed, let x0 = symptom bother score at baseline, x1 = symptom bother score at 13 weeks, and x = x0 - x1. For example, a participant with a symptom bother score of 60 at baseline and a symptom bother score of 20 at 13 weeks would have a change of score on the overactive bladder questionnaire short-form (OAB-q SF) symptom bother subscale from baseline to 13 weeks of -40.
Score on a Global Response Assessment (GRA) Scale at 13 Weeks	13 weeks	The global response assessment (GRA) scale ranges from 1 to 6, with 1 corresponding to markedly worse and 6 corresponding to markedly better, so that higher scores represent better outcomes..
Threshold at 13 Weeks	13 weeks	Neuromodulation pulse amplitude required to evoke paresthesia or motor response (threshold) at 13 weeks.

Countries

United States

Participant flow

Participants by arm

Arm	Count
Study Device Subjects who provide informed consent, meet all inclusion criteria, and no exclusion criterion, will have a study device implanted and followed closely for 26 weeks. Implantation and neuromodulation therapy: The study device is an autonomous permanent implant for neuromodulation targeting the posterior tibial nerve. It does not require an external power source or charger.	10
Total	10

Baseline characteristics

Characteristic	Study Device
Age, Categorical <=18 years	0 Participants
Age, Categorical >=65 years	7 Participants
Age, Categorical Between 18 and 65 years	3 Participants
Age, Continuous	68.4 years STANDARD_DEVIATION 9.5
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	9 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants
Met inclusion criterion for frequency, based on pre-therapy diary	2 Participants
Met inclusion criterion for incontinence, based on pre-therapy diary	7 Participants
Met inclusion criterion for nocturia, based on pre-therapy diary	7 Participants
Met inclusion criterion for urgency, based on pre-therapy diary	10 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants
Race (NIH/OMB) Asian	1 Participants
Race (NIH/OMB) Black or African American	0 Participants
Race (NIH/OMB) More than one race	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) White	9 Participants
Region of Enrollment United States	10 participants
Sex: Female, Male Female	8 Participants
Sex: Female, Male Male	2 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 10
other Total, other adverse events	8 / 10
serious Total, serious adverse events	0 / 10

Outcome results

Primary

Percent Change of Excess Voiding Frequency During Waking Hours From Baseline to 13 Weeks

For a participant analyzed, let x0 = average number of voids during waking hours per 24 hours in first 72 hours of baseline diary, x1 = average number of voids during waking hours per 24 hours in first 72 hours of 13-week diary, and x = percent change of excess voiding frequency during waking hours from baseline to 13 weeks, where excess means voids during waking hours exceeding 7 per 24 hours. Then x = 100 \* (x1 - x0) / (x0 - 7). For example, a participant with an average of 16 voids during waking hours per 24 hours in the first 72 hours of the baseline diary and an average of 10 voids during waking hours per 24 hours during the first 72 hours of the 13-week diary would have a percent change of excess voiding frequency during waking hours from baseline to 13 weeks of 100 \* (10 - 16) / (16 - 7) = -67.